Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo

Cellular Immunology

Volumn 271, Issue 1, 2011, Pages 67-72

  Noori, Shokoofe ^a   Hassan, Zuhair M ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Dihydroartemisinin; IFN ; IL 4; Immuno modulator; T regulatory cell (Treg cell)

Indexed keywords

DIHYDROARTEMISININ; GAMMA INTERFERON; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CELL VIABILITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TH1 CELL; TUMOR VOLUME;

ANIMALS; ANTIMALARIALS; ARTEMISININS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HINDLIMB; HYPERSENSITIVITY, DELAYED; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAPERITONEAL; INTERFERON-GAMMA; INTERLEUKIN-4; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; SHEEP; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TUMOR BURDEN;

ANIMALIA;

EID: 80052397480     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.06.008     Document Type: Article

References (33)

1. Klayman D.L. Qinghaosu (artemisinin): an antimalarial drug from china. Science 1985, 228:1049-1055.
2. Ying Lu., Tong C.H., Jun Q.U., Wen Pa., Sun Lei., Xun-Bin W.E. Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung denocarcinoma ASTC-a-1 cells. J. Biomed. Sci. 2009, 16:1-15.
3. Kim S.J., Kim M.S., Lee J.W., Lee C.H., Yoo H.S., Shin H.M., Park J., Lee S.H. Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. Cancer. Res. Clin. Oncol. 2006, 132:129-135.
4. Colm M., Byron G., Jeffrey W., Roman G., Funda V., David R., Robert L., Tomikazu S. Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs 2010, 21:423-432.
5. Lai H., Singh N.P. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett. 1995, 91:41-46.
6. Ikuhiko N., Henry L., Narendra P., Singh T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int. J. Pharm. 2008, 354:28-33.
7. Efferth T., Benakis A., Romero M., Tomicic M., Rauh R., Steinbach D., Häfer R. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic. Biol. Med 2004, 37:998-1009.
8. Efferth T., Davey M., Olbrich A., Rücher G., Gebbart E., Daveu R. Activity of drugs from traditional Chinese medicine towards sensitive and MDRI- or MRPI-overexpressing multidrug-resistant humanCCRF-CEM leukenna cells. Blood Cells Mol. Dis. 2002, 28:160-168.
9. Takayuki Fu., Kumar Fe., Decha Pi., Zhihe Li., Ken Fuj Human fortilin is a molecular target of dihydroartemisinin. FEBS Lett. 2008, 582:1055-1060.
10. Aristo Vo., Jonathan Er. Regulatory T Cells, a Potent Immunoregulatory Target for CAM Researchers: modulating tumor immunity, autoimmunity and alloreactive immunity (III). Adv. Access Publ. 2006, 3:309-316.
11. Franc Oi., Ghiringhelli Ni., Larmonier El., Schmitt Ar. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004, 34:336-344.
12. Rao H., Prabhala Pa., Neri Jo., Pierfrancesco Ta., Masood A., Shammas Ch. Dysfunctional T regulatory cells in multiple myeloma for personal use only. Blood 2006, 107:300-304.
13. Hui L., Jin-Pu Y., Shui C., Feng W., Peng Z., Xiu-Mei A., Zong-Tang H., Xiu-Bao R. CD4+ CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J. Clin. Immunol. 2007, 27:317-326.
14. Chien Hu., Shih Lin., Pao Li., Su Yo., Chi Ya. The Immunopharmaceutical effects and mechanisms of herbmedicine. Cell. Mol. Immunol. 2008, 5:23-31.
15. Hassan Z.M., Yaraee R., Zare N., Ghazanfari T., Sarraf Nejad A., Nazori B. Immunomodulatory affect of R10 fraction of garlic extract on natural killer activity. Int. Immunopharmacol. 2003, 3:1483-1489.
16. O'Garra A., Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell. Biol. 2000, 10:542-550.
17. Wen-liang Z., Jin-ming W.U., Qing-li W.U., Jun-xia W.A., Yu Z., lan H. A novel artemisinin derivative, 3-(12-β-artemisininoxy) phenoxyl succinic acid (SM735), mediates immunosuppressive effects in vitro and in vivo. Acta Pharmacol. Sin. 2005, 26:1352-1358.
18. Zhang J.X., Wang J.X., Zhang Y., Zuo J.P., Wu J.M., Sui Y., Li Y. Synthesis and immunosuppressive activity of new artemisinin derivatives containing polyethylene glycol group. Yao Xue Xue Bao 2006, 41:65-70.
19. Noori Sh., Naderi G., Hassan Zu., Habibi Zo. Immunosuppressive activity of a molecule isolated from Artemisia annua on DTH responses compared with cyclosporin A. Int. Immunopharmacol. 2004, 4:1301-1306.
20. Lai Jh., Ho Lj., Kwan Cy., Chang Dm., Lee Tc. Plant alkaloid tetrandrine and its analog block CD28-costimulated activities of human peripheral blood T cells: potential immunosuppressants in transplantation immunology. Transplantation 1999, 68:1383-1392.
21. Wen-liang H.U., YAO Li. Anti-tumor mechanism of Artemisinin. China Pharm. 2008, 36:123-136.
22. Rao H., Prabhala Pa., Neri Jo., Pierfrancesco Ta., Masood A. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006, 107:301-304.
23. Jiao Y., Ge Cm., Meng Qh. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol. Sinica. 2007, 28:1045-1056.
24. Veerasubramanian P., Gosi P., Limsomwong C., Walsh D.S. Artesunate and a major metabolite, dihydroartemisinin, diminish mitogen-induced lymphocyte proliferation and activation. Southeast Asian J. Trop. Med. Public Health 2006, 37:838-847.
25. Yang Si., Xun X., Shu M., Long Ga., Han Li., Long Gh. Enhancem ent of interleukin 2 production and its m RNA expression by dihydroartemisinin. Aeta Phar eologiea Sinic 1994, 6:515-520.
26. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004, 22:531-562.
27. Bluestone J.A., Abbas A.K. Natural versus adaptive regulatory T cells. Nat. Rev. immunol. 2003, 3:253-257.
28. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2001, 101:455-458.
29. Helen Y., Wang De., Lee Gu., Peng Zh., Guo Y., Yukiko Ki. Tumor-specific human CD4_ regulatory T Cells and their ligands. Implications for Immunother. Immun. 2004, 20:7-118.
30. Daniel Hi., Gabrielle A., Rizzuto Ta., Adam D., Francesca Av. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J. Exp. Med. 2007, 206:1103-1116.
31. Ichiki Y., Bowlus C.L., Shimoda S., Ishibashi H., Vierling J.M., Gershwin M.E. T cell immunity and graft-versus-host disease (GVHD). Autoimmun. Rev. 2006, 5:1-9.
32. Adeegbe D., Bayer A.L., Levy R.B., Malek T.R. Cuttingedge: allo- geneicCD4+CD25+Foxp3+T regulatory cells suppress autoimmunityWhile establish ingtransplantation tolerance. J. Immunol. 2006, 176:7149-7153.
33. Hui Li., Jin_Pu Yu., Shui C., Feng W. CD4+ CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J. Clin. Immunol. 2007, 27:317-324.